Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of HIPRA COVID-19 vaccine as booster after primary COVID-19 vaccination
TCTR20220317003Phase 2Not yet recruiting
- Sponsor
- Thammasat University Hospital
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of PHH-1V in coronavirus disease 2019 (COVID-19), sponsored by Thammasat University Hospital. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220317003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220317003.